Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 10/20 | 0.54 |
| ▸ | NPC1 | O15118 | 9/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.52 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4912591 | 0.82 | NPC1 (0.59) | RAB9ANPC1SMN1; SMN2HTTHIF1A | |
| SCHEMBL4915419 | 0.78 | NPC1 (0.78) | RAB9ANPC1SMN1; SMN2HTTHIF1A | |
| SCHEMBL4920158 | 0.77 | NOTUM (0.68) | RAB9ANPC1SMN1; SMN2HTTTP53 | |
| SCHEMBL5175836 | 0.76 | HIF1A (0.53) | RAB9ANPC1SMN1; SMN2HTTHIF1A | |
| SCHEMBL4998852 | 0.76 | HRH3 (0.64) | RAB9ANPC1SMN1; SMN2HTTHIF1A | |
| SCHEMBL4921397 | 0.76 | HIF1A (0.55) | RAB9ANPC1SMN1; SMN2HTTHIF1A | |
| SCHEMBL4922787 | 0.75 | NPC1 (0.65) | RAB9ANPC1SMN1; SMN2HIF1AEPAS1 | |
| SCHEMBL15932601 | 0.74 | NPC1 (0.69) | RAB9ANPC1SMN1; SMN2HTTHIF1A | |
| SCHEMBL31010354 | 0.74 | DRD2 (0.70) | DRD2DRD4DRD3SMN1; SMN2HRH3 | |
| SCHEMBL13701851 | 0.73 | KMT2A (0.58) | SMN1; SMN2HTTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | claimed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | claimed |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1786422-A2 | ARYL UREA DERIVATIVES FOR TREATING OBESITY | Prosidion Limited (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006018662-A2 | ARYL UREA DERIVATIVES FOR TREATING OBESITY | PROSIDION LIMITED (GB) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | DRD2 2330/4885DRD4 3220/4885DRD3 2252/4885 |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | DRD2 2330/4885DRD4 3220/4885DRD3 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.